| Product NDC: | 63304-255 |
| Proprietary Name: | Pioglitazone |
| Non Proprietary Name: | Pioglitazone |
| Active Ingredient(s): | 30 mg/1 & nbsp; Pioglitazone |
| Administration Route(s): | ORAL |
| Dosage Form(s): | TABLET |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 63304-255 |
| Labeler Name: | Ranbaxy Pharmaceuticals Inc |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | ANDA202467 |
| Marketing Category: | ANDA |
| Start Marketing Date: | 20130207 |
| Package NDC: | 63304-255-05 |
| Package Description: | 500 TABLET in 1 BOTTLE (63304-255-05) |
| NDC Code | 63304-255-05 |
| Proprietary Name | Pioglitazone |
| Package Description | 500 TABLET in 1 BOTTLE (63304-255-05) |
| Product NDC | 63304-255 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | Pioglitazone |
| Dosage Form Name | TABLET |
| Route Name | ORAL |
| Start Marketing Date | 20130207 |
| Marketing Category Name | ANDA |
| Labeler Name | Ranbaxy Pharmaceuticals Inc |
| Substance Name | PIOGLITAZONE HYDROCHLORIDE |
| Strength Number | 30 |
| Strength Unit | mg/1 |
| Pharmaceutical Classes | Peroxisome Proliferator Receptor alpha Agonist [EPC],Peroxisome Proliferator Receptor gamma Agonist [EPC],Peroxisome Proliferator-activated Receptor Activity [MoA],PPAR alpha [Chemical/Ingredient],PPAR gamma [Chemical/Ingredient],Thiazolidinedione [EPC],Thiazolidinediones [Chemical/Ingredient] |